AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03216980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Healthy Control Antioxidant
Description: Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
Study NCT03216980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Control Antioxidant
Description: Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
Study NCT03216980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Healthy Control Placebo
Description: Subjects will ingest placebo (microcrystalline cellulose) pills.
Study NCT03216980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Control Placebo
Description: Subjects will ingest placebo (microcrystalline cellulose) pills.
Study NCT00357240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: Capsules, Oral, 400 mg, once daily, 6 days.
Study NCT00357240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir/Ritonavir
Description: Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
Study NCT00357240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir+Omeprazole
Description: Capsules/capsules + Capsules, Oral, 300/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
Study NCT00849186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: oral
Study NCT00849186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: IV
Study NCT00849186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Surgery
Study NCT04152187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The treatment group will receive inspiratory muscle training.
Study NCT04579016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAIGE2 lifestyle intervention
Description: Education session during pregnancy. provision of fitness tracker, referral to commercial weight management organization, text and phone support
Study NCT00357240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir+Omeprazole
Description: Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
Study NCT04193904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRx0518
Description: MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
Study NCT04193904 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Preoperative Radiation
Description: Radiation will be delivered as 30Gy/10 fractions over two weeks.
Study NCT00720967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Heart Surgery (OHS)
Description: General anesthesia, use of iodine impregnated adhesive dressing, median sternotomy and/or thoracotomy incision, full heparinization (300-400 ui/kg), arterial and venous cannulation, initialization of CPB with or without aortic cross-clamping and high-potassium cold cardioplegia, surgical repair under mild-moderate hypothermia. De-clamping (if cross clamp was applied), neutralization of heparin by protamin, de-cannulation and hemostasis after surgical repair. Insertion of drain(s) and pacing wire(s). Closure of all layers in anatomical plan.
Study NCT00720967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Heart Surgery (OHS)
Description: General anesthesia, use of iodine impregnated adhesive dressing, median sternotomy and/or thoracotomy incision, full heparinization (300-400 ui/kg), arterial and venous cannulation, initialization of CPB with or without aortic cross-clamping and high-potassium cold cardioplegia, surgical repair under mild-moderate hypothermia. De-clamping (if cross clamp was applied), neutralization of heparin by protamin, de-cannulation and hemostasis after surgical repair. Insertion of drain(s) and pacing wire(s). Closure of all layers in anatomical plan.
Study NCT00357240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir+Omeprazole
Description: Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in AM, 7 days.
Study NCT00357240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir+Omeprazole
Description: Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in PM, 7 days.
Study NCT03966872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Illness Management and Recovery
Description: Education and skills training groups on illness management of chronic medical and psychiatric illness.
Study NCT03966872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program
Description: Education and skills training groups on illness management of chronic conditions
Study NCT00720967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Modified Ultrafiltration (MUF)
Description: Once the surgical repair is finished, and CPB will be stopped after aortic declamping. The arterial and venous cannulae will be connected to each other using 3-way connectors and a cardioplegia line. When hemodynamic stability is established (MAP >75 mmHg, CVP > 12 mmHg, Htc > 25%), blood will be drained from the arterial cannula using a roller pump, driven to the ultrafilter, and eventually to the venous cannula. The blood flow will be maintained at \~150 mL/min, and suction will be applied to the filtrate port to achieve an ultrafiltration of 100-120 mL/min. Heat exchanger and bubble trap of the cardioplegia line will be used to maintain the filtered blood at body temperature and to prevent air embolism, respectively. MUF will continue 20 minutes. The filtered volume will be collected.
Study NCT00720967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Description: Two HD sessions will be performed at 3 days and 1 day prior to surgery. Each session will last 3 hours if the patient weighs \< 75 kg, and 4 hours if > 75 kg. Conventional HD will be carried out using a volume-controlled dialysis machine. A bicarbonate dialysate containing K (3 mmol/L), Ca (1.5 mmol/L) and HCO3 (31 mmol/L) will be used. Sodium conductivity will be set at 138 mmol/L. Medium-flow filters will be used as artificial kidney devices. Dialysate temperature will be set at 36oC. Dialysate and blood flow rate will be set at 500 mL/min and 250-300 ml/min, respectively. Intradialytic ultrafiltration will not be used routinely unless the patient has volume overload. The decision to use intradialytic ultrafiltration will be taken with the anaesthesiologist and the cardiac surgeon. If intradialytic ultrafiltration is indicated, maximal rate of ultrafiltration will be 10 ml/kg/hour. These patients will undergo open heart surgery after two sessions of HD.
Study NCT03734926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1241
Description: ZSP1241 tablets for oral administration.
Study NCT03699397 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dry electrode EEG
Description: A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. To do this, the investigators will use the WaveguardTM dry electrode EEG cap and compatible eegoTM amplifier, developed by ANT Neuro B.V. Netherlands and both CE marked as medical devices in the European Union (see appendices 1 and 2). Both products will be used within the intended use as described in the user manuals. The dry electrode cap is put on the patients head and records the EEG signal for several minutes; the amplifier is used to amplify the EEG signal and reduce artefacts.
Study NCT01832493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy
Description: All study patients were evaluated for the optimal atrial-ventricular (AV) programmed interval using various methods.
Study NCT02158962 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral - Education
Description: Behavioral - Education~3 educational sessions aimed at reducing risks partner violence, and sexual transmitted infections
Study NCT01536561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)
Description: 131-I anti-B1 is the product of 131-I labeling of the anti-CD20 murine monoclonal antibody and the anti-B1 antibody itself is an intact IgG2a murine monoclonal antibody which has specificity far the CD20 antigen on human B cells. Anti-B1 is a clear, colorless liquid. 131-I labeling of the anti-B1 antibody will be carried out by iodogen technique. Trace labeling of the antibody will involve the labeling of approximately 1 to 3 mg of antibody with 5 mCi of 131-I.
Study NCT03827967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PalloV-CC
Description: The PalloV-CC vaccine uses yeast cell wall particles (YCWP) to serve as an efficient vaccine delivery system as they can contain a broad range of antigenic material, they are rapidly phagocytized by antigen presenting cells, and they are inherently immunogenic. The PalloV-CC vaccine utilizes silicate-capped YCWP to deliver allogenic colon cancer tumor lysate. The vaccine will be given to subjects with resectable colon cancers neoadjuvantly shortly before surgery in order to study the effect of the vaccine on the tumor microenvironment using a well-validated immune scoring system for colon cancer and other immunologic tests.
Study NCT04579016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Care routinely provided to all pregnant women diagnosed with GDM
Study NCT01527812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Description: We will perform an ultrasound guided femoral nerve block. For locating the nerve a 5 cm, 6-13 MHz linear probe (Sonosite Turbo M, Bothwell WA, USA) will be used. After the examination of the anatomy of the femoral artery we will fix the probe transversal to the thigh below the inguinal crease and above the ramification of deep femoral artery and make skin marks on this position. A 22 G 50 mm long Stimuplex BBraun needle will be used. 15 ml 2 % lignocaine will be injected.
Study NCT04258449 — intervention group
Intervention type: DEVICE
Intervention: DOvEEgene Fleur Sampling
Description: Patients will undergo uterine sampling with DOvEEgene Fleur endometrial sampling device prior to surgical intervention, in addition to standard of care treatment.
Study NCT01550614 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Alferminogene tadenovec
Description: One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)
Study NCT04584944 — intervention group
Intervention type: RADIATION
Intervention: Dual energy X-ray absorptiometry
Description: Evaluation of the appendicular muscle mass of the limbs will be performed by Dual-Energy X-ray Absorptiometry, using a QDR 4500. Body composition analysis will also be evaluated with TANITA Body Composition Analyzer device,model BC-418MA. Bioelectrical Impedance Analysis measures the body composition using a constant power source (high frequency current 50kHz, 90 μA).~Muscle mass is also going to be measured by using ultrasound -U/S. It measures basic parameters such as muscle volume and spectrum length through the B-Mode imaging with Linear 7-12MHz frequency heads that can reliably determine the thickness and transverse incisions of the superficial muscular Groups.
Study NCT00144781 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Description: 0.58 mg/kg every week
Study NCT00144781 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Description: 1.2 mg/kg every week
Study NCT00144781 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Description: 1.2 mg/kg every other week
Study NCT00144781 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Description: 1.8 mg/kg every other week
Study NCT01672216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation
Study NCT01672216 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMG-biofeedback alone
Study NCT00587990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lower dose mesenchymal stem cell (MSC) injection
Description: Participants will receive between 10 and 20 intramyocardial injections of 2 million MSCs per 0.25-0.5 cubic centimeter (cc) for a total of 2 x 10\^7 cells. The injections will be administered following completion of CABG surgery.
Study NCT00587990 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive between 10 and 20 placebo injections that consist of phosphate buffered saline (PBS) and 1% human serum albumin (HSA).
Study NCT00587990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Higher dose MSC injection
Description: Participants will receive between 10 and 20 intramyocardial injections of 20 million MSCs per 0.25-0.5 cc for a total of 2 x 10\^8 cells. The injections will be administered following completion of CABG surgery.
Study NCT01664611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Conditioning administered via the inflation of a blood pressure cuff on the upper arm
Description: Suprasystolic blood pressure cuff inflation for set periods to time to render a limb ischaemic followed by periods of deflation to allow for reperfusion.
Study NCT01664611 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham conditioning
Description: Non therapeutic inflation of a blood pressure cuff that does not cause ischaemia/reperfusion injury
Study NCT00553436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Apposition System (TAS) Device
Description: Closure of defect following polypectomy using the Tissue Apposition System (TAS) Device.
Study NCT02896335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Administered orally once per day on days 1-21 of 28-day cycles.
Study NCT02896335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered via intravenous (IV) infusion at a dose of 200 mg over 30 minutes once every 21 days. Pembrolizumab cycles are 3 weeks (21 days) long in this study, and participants in Cohort 2 can receive pembrolizumab as long as they are receiving study drug palbociclib.
Study NCT00630487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
Study NCT00630487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Fixed doses for patients: MALE: \< 45y 0,4 mg, > 45y 0,2mg FEMALE: \< 45y 0,5mg, >45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
Study NCT03102853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic diet
Study NCT03102853 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control diet
Study NCT01030952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nateglinide
Description: Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
Study NCT01102504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01102504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ateronon
Description: Tomato extract containing 28 mg lycopene/ day
Study NCT03706105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: 3 x week \~1 hour of exercise + education
Study NCT01084473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
Study NCT01030952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
Study NCT01454505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-53817 nasal spray solution
Description: Active ingredients administered in 1 of 3 concentrations during Stage A to determine maximum tolerated dose (MTD), and administered at maximum tolerated dose during Stage B.
Study NCT01454505 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle nasal spray
Description: Inactive ingredients used as placebo comparator during Stage A and Stage B.
Study NCT04322435 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continuous blood glucose measurement
Description: Continuous blood glucose measurement with Abbott Freestyle Pro for 14 days, repeated twice at 6 months intervals.
Study NCT04322435 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of capillary blood glucose
Description: Measurement of capillary blood glucose :~* In the morning on an empty stomach, every first week of each month for 12 months.~* In case of suspicion of hypoglycaemia (parental assessment). Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the Accu-Chek Performa strips.
Study NCT05242068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veinlite
Description: Use of vein imaging device for visualization of veins during peripheral IV placement
Study NCT05242068 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Patients received standard intravenous catheterization.
Study NCT04736290 — intervention group
Intervention type: OTHER
Intervention: NLR
Description: Calculation of NLR
Study NCT04736290 — intervention group
Intervention type: OTHER
Intervention: PLR
Description: Calculation of PLR
Study NCT03544424 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01084473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
Study NCT01084473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9 % NaCl will be infused.
Study NCT01732510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8226
Description: MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
Study NCT03181334 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Branch I
Description: FIT kits and a Standard (control) invitation letter to complete CRC screening is mailed to the homes of eligible patients.
Study NCT01922986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS
Description: 10 minutes of real high-frequency (6-Hz) rTMS priming (total priming pulses = 600) plus 10 minutes of low-rate (1Hz) rTMS (total low-rate pulses = 600).
Study NCT03181334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Branch II
Description: FIT kits and a Brief Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch II: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week.
Study NCT01732510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered IV every 2 weeks for a period of 12 weeks.
Study NCT01582516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: delta-24-RGD adenovirus
Description: slow continuous microinfusion in and around the brain tumor during 44 hrs.by 4 temporary placed catheters